Compare Ascendis Pharma A/S (ASND) vs Veritone Inc (VERI) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Ascendis Pharma A/S vs Veritone Inc — how do they compare? Ascendis Pharma A/S trades at $270.99 (market cap $17.74B), while Veritone Inc trades at $1.17 (market cap $109.22M). The key difference: Ascendis Pharma A/S is far larger — about 162.4× Veritone Inc's market cap, and Ascendis Pharma A/S is trading nearer its 52-week high, Veritone Inc nearer its low. Which is the better fit depends on your goals.
| ASND | VERI | |
|---|---|---|
Market Cap | $17.74B | $109.22M |
Sector | Health | Technology |
52-Week High | $277.18 | $8.39 |
52-Week Low | $163.32 | $1.18 |
Enterprise Value | $18.11B | $141.25M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $270.45, down 1.81% on the day, with a bullish technical outlook supported by moving averages and positive analyst sentiment. The company reported Q1 2026 revenue of $241 million (converted from €197 million for YORVIPATH and €44 million for SKYTROFA, Q1 2026 earnings report May 7, 2026) and beat EPS expectations, while recent news highlights clinical progress in achondroplasia and hypoparathyroidism treatments. Valuation ratios are elevated with a P/E of 31.38 and P/S of 16.94, reflecting growth expectations.
The outlook is positive due to strong revenue growth, multiple product launches, and a 92% analyst buy rating with a $321.17 price target. Key risks include high debt levels, persistent net losses despite improving margins, and reliance on successful commercialization of new therapies. The stock's upside depends on execution of growth strategy and achieving profitability.
Veritone (VERI) trades at $1.18, down 1.67% on the day, amid a bearish technical outlook and significant financial challenges. The company reported a net loss of $111.73 million in 2025, with negative profit margins and cash flow from operations. Recent news is dominated by multiple securities class action lawsuits alleging accounting irregularities, with a key deadline of July 20, 2026.
The outlook remains highly risky due to persistent losses, legal overhangs, and negative investor sentiment. While analyst consensus suggests substantial upside to a $5.25 price target, fundamental weaknesses and ongoing litigation present severe headwinds for shareholder value recovery in the near term.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About Veritone Inc
Veritone is a leading provider of enterprise AI software and solutions, centered on its proprietary AI operating system, aiWARE™. The platform orchestrates a vast ecosystem of machine learning models to transform unstructured data—such as audio, video, and text—into actionable intelligence. Serving the media, entertainment, and public sectors, Veritone is a critical infrastructure partner for organizations looking to monetize data archives and operationalize AI at scale.
Read more on VERI →
